# Erasca (ERAS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ERAS
## Company Profile
- Ticker: ERAS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 18.62 USD
- Market cap: 4192071626.1600003 USD
- Last updated: 2026-08-05
## Business Overview
### RAS/MAPK Precision Oncology
Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct and pathway-level inhibition.
### ERAS-0015
ERAS-0015 is a RAS-targeted clinical candidate being evaluated in tumors including KRAS-mutated non-small cell lung and pancreatic cancers. Development includes monotherapy expansion and combination work with pembrolizumab.
### ERAS-4001
ERAS-4001 is a pan-KRAS inhibitor in Phase 1 dose escalation. The program is intended to broaden coverage across KRAS-driven tumors beyond individual mutation subtypes.
## Why The Stock Is Moving

As of Aug 5, 2026, ERAS closed up 1.31% at $18.62. No new same-company headline was identified in the current news window.

## Future Catalysts

- Preliminary Phase 1 monotherapy data for ERAS-4001 in the second half of 2026.
- ERAS-0015 monotherapy-expansion and combination dose-escalation data in the first half of 2027.

## Drug Assets

- ERAS-0015

## Recent News
- 2026-07-15 20:01 EST — [Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/ERAS/erasca-announces-closing-of-upsized-public-offering-of-common-stock-including-fu-dbcc43e8) — Source: Erasca
- 2026-07-14 03:10 EST — [Erasca Announces Pricing of Upsized Public Offering of Common Stock](https://biopharmsignal.com/news/ERAS/erasca-announces-pricing-of-upsized-public-offering-of-common-stock-fbb7f193) — Source: Erasca
- 2026-07-13 20:19 EST — [Erasca Announces Proposed Public Offering of $500 Million of Common Stock](https://biopharmsignal.com/news/ERAS/erasca-announces-proposed-public-offering-of-500-million-of-common-stock-f66f583d) — Source: Erasca
- 2026-07-13 20:01 EST — [Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors](https://biopharmsignal.com/news/ERAS/erasca-announces-updated-preliminary-phase-1-data-and-registration-enabling-plan-3c4d65b6) — Source: Erasca
- 2026-05-27 12:00 EST — [Erasca to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ERAS/erasca-to-present-at-the-jefferies-global-healthcare-conference) — Source: Erasca